Pablo G. Legorreta - Net Worth and Insider Trading
Pablo G. Legorreta Net Worth
The estimated net worth of Pablo G. Legorreta is at least $181 Million dollars as of 2024-12-28. Pablo G. Legorreta is the CEO, Chairman of the Board, 10% Owner of Royalty Pharma PLC and owns about 3,748,980 shares of Royalty Pharma PLC (RPRX) stock worth over $96 Million. Pablo G. Legorreta is the Director, 10% Owner of Epizyme Inc and owns about 31,833,334 shares of Epizyme Inc (EPZM) stock worth over $47 Million. Pablo G. Legorreta is also the Director, 10% Owner of ProKidney Corp and owns about 22,617,909 shares of ProKidney Corp (PROK) stock worth over $38 Million. Details can be seen in Pablo G. Legorreta's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Pablo G. Legorreta has not made any transactions after 2024-06-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Pablo G. Legorreta
Pablo G. Legorreta Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Pablo G. Legorreta owns 4 companies in total, including Royalty Pharma PLC (RPRX) , Epizyme Inc (EPZM) , and Social Capital Suvretta Holdings Corp III (DNAC) among others .
Click here to see the complete history of Pablo G. Legorreta’s form 4 insider trades.
Insider Ownership Summary of Pablo G. Legorreta
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
RPRX | Royalty Pharma PLC | 2023-06-28 | director & CEO & Chairman of the Board |
EPZM | Epizyme Inc | 2022-01-31 | director |
DNAC | Social Capital Suvretta Holdings Corp III | 2022-07-11 | director & 10 percent owner |
2024-06-13 | director & 10 percent owner |
Pablo G. Legorreta Latest Holdings Summary
Pablo G. Legorreta currently owns a total of 3 stocks. Among these stocks, Pablo G. Legorreta owns 3,748,980 shares of Royalty Pharma PLC (RPRX) as of June 28, 2023, with a value of $96 Million and a weighting of 52.9%. Pablo G. Legorreta owns 31,833,334 shares of Epizyme Inc (EPZM) as of January 31, 2022, with a value of $47 Million and a weighting of 25.85%. Pablo G. Legorreta also owns 22,617,909 shares of ProKidney Corp (PROK) as of June 13, 2024, with a value of $38 Million and a weighting of 21.24%.
Latest Holdings of Pablo G. Legorreta
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
RPRX | Royalty Pharma PLC | 2023-06-28 | 3,748,980 | 25.54 | 95,748,949 |
EPZM | Epizyme Inc | 2022-01-31 | 31,833,334 | 1.47 | 46,795,001 |
PROK | ProKidney Corp | 2024-06-13 | 22,617,909 | 1.70 | 38,450,445 |
Holding Weightings of Pablo G. Legorreta
Pablo G. Legorreta Form 4 Trading Tracker
According to the SEC Form 4 filings, Pablo G. Legorreta has made a total of 4 transactions in Royalty Pharma PLC (RPRX) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Royalty Pharma PLC is the acquisition of 130,000 shares on June 28, 2023, which cost Pablo G. Legorreta around $4 Million.
According to the SEC Form 4 filings, Pablo G. Legorreta has made a total of 1 transactions in Epizyme Inc (EPZM) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Epizyme Inc is the acquisition of 22,666,667 shares on January 31, 2022, which cost Pablo G. Legorreta around $34 Million.
According to the SEC Form 4 filings, Pablo G. Legorreta has made a total of 1 transactions in ProKidney Corp (PROK) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in ProKidney Corp is the acquisition of 22,617,909 shares on June 13, 2024, which cost Pablo G. Legorreta around $55 Million.
Insider Trading History of Pablo G. Legorreta
- 1
Pablo G. Legorreta Trading Performance
GuruFocus tracks the stock performance after each of Pablo G. Legorreta's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Pablo G. Legorreta is -17.87%. GuruFocus also compares Pablo G. Legorreta's trading performance to market benchmark return within the same time period. The performance of stocks bought by Pablo G. Legorreta within 3 months outperforms 0 times out of 6 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Pablo G. Legorreta's insider trading performs compared to the benchmark.
Performance of Pablo G. Legorreta
Pablo G. Legorreta Ownership Network
Pablo G. Legorreta Owned Company Details
What does Royalty Pharma PLC do?
Who are the key executives at Royalty Pharma PLC?
Pablo G. Legorreta is the director & CEO & Chairman of the Board of Royalty Pharma PLC. Other key executives at Royalty Pharma PLC include 10 percent owner Avara Management Ltd , EVP & CFO Terrance P. Coyne , and EVP & Investments & GC George W. Lloyd .
Royalty Pharma PLC (RPRX) Insider Trades Summary
Over the past 18 months, Pablo G. Legorreta made no insider transaction in Royalty Pharma PLC (RPRX). Other recent insider transactions involving Royalty Pharma PLC (RPRX) include a net sale of 934,197 shares made by Avara Management Ltd , a net sale of 150,000 shares made by Terrance P. Coyne , and a net sale of 470,000 shares made by Rory B Riggs .
In summary, during the past 3 months, insiders sold 0 shares of Royalty Pharma PLC (RPRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,554,197 shares of Royalty Pharma PLC (RPRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,554,197 shares.
Royalty Pharma PLC (RPRX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Royalty Pharma PLC Insider Transactions
Pablo G. Legorreta Mailing Address
Above is the net worth, insider trading, and ownership report for Pablo G. Legorreta. You might contact Pablo G. Legorreta via mailing address: 110 E 59th Street, Suite 3300, New York Ny 10022.